Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Nov 20;99(47):e23263.
doi: 10.1097/MD.0000000000023263.

Simultaneous renal clear cell carcinoma and primary clear cell carcinoma of the liver: A case report

Affiliations
Case Reports

Simultaneous renal clear cell carcinoma and primary clear cell carcinoma of the liver: A case report

Hua Jiang et al. Medicine (Baltimore). .

Abstract

Rationale: Double primary clear cell carcinomas of the liver (PCCCL) and kidney are extremely rare; moreover, there have been no reported cases of adrenal metastasis from primary clear cell tumors of the liver.

Patient concerns: A 47-year-old male patient was admitted to our clinic with space-occupying lesions in the left kidney and liver during a regular medical examination.

Diagnoses: The tumors in the kidney and liver were diagnosed as primary clear cell carcinoma by histopathological examination.

Interventions: The patient subsequently underwent nephron-sparing surgery of the left kidney and radical partial excision of the right liver lobe by laparoscopic surgery. Transcatheter arterial chemoembolization (TACE) was performed for the patient 2 weeks after tumor resection. One month after the operation, the patient started adjuvant therapy with sorafenib (400 mg twice per day orally). However, follow-up CT imaging revealed a solid mass measuring 1.9 × 2.0 × 2.0 cm in the right adrenal gland at 2 months postoperatively, and then the patient underwent radiofrequency ablation (RFA) for the right adrenal tumor.

Outcomes: The patient remained cancer free for 2 years following the diagnosis despite early right adrenal metastasis.

Lessons: Hepatocyte immunostaining is sufficient for the diagnosis of PCCCL.

PubMed Disclaimer

Conflict of interest statement

The authors have no funding and conflicts of interests to disclose.

Figures

Figure 1
Figure 1
CT prior to nephron-sparing surgery of the left kidney and radical partial excision of the right liver lobe. (A) The enhanced computed tomography (CT) scan revealed a mildly enhanced tumor measuring approximately 3 × 4 × 5 cm3 in the right lobe of the liver. (B) Another significantly enhanced mass measuring approximately 2 × 3 × 3 cm3 was observed in the inferior pole of the left kidney without local invasion or lymph node metastases, and no mass lesions were found on the bilateral adrenal glands.
Figure 2
Figure 2
HE and immunological staining of the hepatic tumor: (A) Bulky cancer cells with entirely or almost entirely “clear” cytoplasm were found in the tumor (original magnification × 400); (B) hepatocyte staining revealed strong positivity in the tumor cells (original magnification × 400); (C) CD10 staining of the tumor cells was completely negative (original magnification × 400).
Figure 3
Figure 3
HE and immunological staining observation of the renal tumor: (A) Sheet of clear cells in the tumor (original magnification × 400); (B) CD10 staining revealed diffuse positivity among the tumor cells (original magnification × 400); (C) hepatocyte staining of tumor cells was completely negative (original magnification × 400).
Figure 4
Figure 4
Images of the right adrenal metastasis 2 months after radical partial excision of the right liver lobe. (A) Enhanced CT scan shows a tumor in the right adrenal gland; (B) 3 months after radiofrequency ablation, the tumor had been completely ablated and devascularized, with the disappearance of tumor enhancement.

Similar articles

Cited by

References

    1. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27: suppl 5: 58–68. - PubMed
    1. Demandante CG, Troyer DA, Miles TP. Multiple primary malignant neoplasms: case report and a comprehensive review of the literature. Am J Clin Oncol 2003;26:79–83. - PubMed
    1. Liu Z, Liu C, Guo W, et al. Clinical analysis of 152 cases of multiple primary malignant tumors in 15,398 patients with malignant tumors. PLoS One 2015;10:e0125754. - PMC - PubMed
    1. Zhai C, Cai Y, Lou F, et al. Multiple primary malignant tumors - a clinical analysis of 15,321 patients with malignancies at a single center in China. J Cancer 2018;9:2795–801. - PMC - PubMed
    1. Spratt JS, Jr, Hoag MG. Incidence of multiple primary cancers per man-year of follow up: 20-year review from the Ellis Fischel State Cancer Hospital. Ann Surg 1966;164:775–84. - PMC - PubMed

Publication types

MeSH terms